| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NAPA |
| Uniprot No | P54920 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-295aa |
| 氨基酸序列 | MDNSGKEAEA MALLAEAERK VKNSQSFFSG LFGGSSKIEE ACEIYARAAN MFKMAKNWSA AGNAFCQAAQ LHLQLQSKHD AATCFVDAGN AFKKADPQEA INCLMRAIEI YTDMGRFTIA AKHHISIAEI YETELVDIEK AIAHYEQSAD YYKGEESNSS ANKCLLKVAG YAALLEQYQK AIDIYEQVGT NAMDSPLLKY SAKDYFFKAA LCHFCIDMLN AKLAVQKYEE LFPAFSDSRE CKLMKKLLEA HEEQNVDSYT ESVKEYDSIS RLDQWLTTML LRIKKTIQGD EEDLR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于NAPA重组蛋白的虚构参考文献示例，涵盖不同研究角度：
---
1. **文献名称**: *Cloning and Expression of Recombinant Neisseria Adhesin A (NAPA) in Escherichia coli for Vaccine Development*
**作者**: Meyer, T. F., Zhang, Y., & Smith, H. (2005)
**摘要**: 本研究通过PCR扩增NAPA基因并成功将其克隆至大肠杆菌表达系统，优化表达条件后获得高纯度重组蛋白。免疫实验表明，重组NAPA可诱导小鼠产生特异性抗体，提示其作为候选疫苗成分的潜力。
2. **文献名称**: *Structural and Functional Characterization of Recombinant NAPA: Implications for Bacterial Adhesion Mechanisms*
**作者**: Johnson, R. B., Lee, K., & Müller, A. (2008)
**摘要**: 通过X射线晶体学解析重组NAPA的三维结构，揭示其与宿主细胞表面受体结合的活性域。体外实验证实，重组NAPA可竞争性抑制脑膜炎奈瑟菌对上皮细胞的黏附，为抗感染药物设计提供依据。
3. **文献名称**: *Scale-Up Production of Recombinant NAPA Using Pichia pastoris and Immunogenicity Evaluation*
**作者**: Chen, L., Wang, X., & O’Connor, C. D. (2012)
**摘要**: 利用毕赤酵母系统实现重组NAPA的高效分泌表达，优化发酵参数后产量提升至毫克级。动物实验显示，该蛋白可引发Th1/Th2混合免疫应答，支持其作为多价疫苗载体的可行性。
---
**说明**：以上文献为模拟示例，实际研究中请通过PubMed/Google Scholar等平台以“NAPA recombinant protein”“Neisseria adhesin A expression”等关键词检索最新文献。
NAPA (N-acetylglucosamine-1-phosphate transferase) recombinant protein is a biotechnologically engineered protein derived from the catalytic subunit of the GlcNAc-1-phosphotransferase enzyme, which plays a critical role in lysosomal enzyme sorting. This enzyme is essential for the phosphorylation of mannose residues on lysosomal hydrolases, enabling their proper trafficking to lysosomes via the mannose-6-phosphate receptor pathway. Dysregulation of this process is linked to lysosomal storage disorders, making NAPA a focus of therapeutic and diagnostic research.
Produced through recombinant DNA technology, NAPA is typically expressed in mammalian cell systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and functional activity. Its recombinant form allows scalable production with high purity and consistency, addressing challenges in studying native enzymes, which are often low in abundance and difficult to isolate.
NAPA recombinant protein is widely utilized in biochemical assays to investigate lysosomal enzyme biogenesis, substrate specificity, and mutation-related pathologies. It also serves as a tool for screening small-molecule modulators or gene therapies targeting lysosomal disorders like mucolipidosis II/III. Additionally, it aids in developing diagnostic kits to measure enzymatic activity in patient samples. Beyond disease research, NAPA contributes to understanding fundamental cellular processes, including protein trafficking and post-translational modification mechanisms. Its engineered variants (e.g., tagged or truncated forms) further enhance experimental versatility in structural studies and interaction mapping. As precision medicine advances, NAPA recombinant protein remains pivotal in bridging basic science with clinical applications for lysosomal-related diseases.
×
